## Nadia Aspromonte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2571370/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Impact of Heart Team Decisions for Patients With Complex Valvular Heart Disease: A Large, Singleâ€Center Experience. Journal of the American Heart Association, 2022, 11, .	1.6	5
2	Cardiac contractility modulation for patient with refractory heart failure: an updated evidence-based review. Heart Failure Reviews, 2021, 26, 227-235.	1.7	10
3	Heart failure in frail elderly resident in a nurse house: prognostic significance of a multimarker approach. Rivista Italiana Della Medicina Di Laboratorio, 2021, 16, .	0.2	Ο
4	Stay Home! Stay Safe! First Post-Discharge Cardiologic Evaluation of Low-Risk–Low-BNP Heart Failure Patients in COVID-19 Era. Journal of Clinical Medicine, 2021, 10, 2126.	1.0	5
5	Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases. Expert Review of Hematology, 2021, 14, 537-546.	1.0	17
6	Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective. Journal of Clinical Medicine, 2021, 10, 2771.	1.0	19
7	ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure. European Heart Journal Supplements, 2021, 23, C176-C183.	0.0	2
8	Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances. Expert Review of Hematology, 2021, 14, 1115-1128.	1.0	6
9	Genetic background of coronary artery disease: clinical implications and perspectives. Expert Review of Precision Medicine and Drug Development, 2020, 5, 135-144.	0.4	Ο
10	Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 154, 103074.	2.0	12
11	Experience of remote cardiac care during the <scp>COVID</scp> â€19 pandemic: the <scp>Vâ€LAP</scp> â"¢ device in advanced heart failure. European Journal of Heart Failure, 2020, 22, 1050-1052.	2.9	17
12	2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications. Chronic Diseases and Translational Medicine, 2020, 6, 246-250.	0.9	6
13	Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. CardioRenal Medicine, 2020, 10, 277-287.	0.7	82
14	The Italian Outbreak of COVID-19: Conditions, Contributors, and Concerns. Mayo Clinic Proceedings, 2020, 95, 1116-1118.	1.4	16
15	Neutrophil gelatinase-associated lipocalin does not predict acute kidney injury in heart failure. World Journal of Clinical Cases, 2020, 8, 1600-1607.	0.3	1
16	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2019, 10, 1347.	1.3	81
17	Left Ventricular Noncompaction: Cause or Consequence of Myocardial Disease? A Case Report and Literature Review. Cardiology, 2019, 143, 100-104.	0.6	9
18	Bioimpedance vector analysis predicts hospital length of stay in acute heart failure. Nutrition, 2019, 61, 56-60.	1.1	34

#	Article	IF	CITATIONS
19	A simple prognostic index in acute heart failure. Minerva Cardioangiologica, 2019, 67, 73-78.	1.2	3
20	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. Heart Failure Reviews, 2018, 23, 469-479.	1.7	4
21	The effects of heart rate control in chronic heart failure with reduced ejection fraction. Heart Failure Reviews, 2018, 23, 527-535.	1.7	12
22	Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1273-1285.	1.5	6
23	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. European Heart Journal Supplements, 2018, 20, F1-F74.	0.0	25
24	A multicenter feasibility study on ultrafiltration via a single peripheral venous access in acute heart failure with overt fluid overload. International Journal of Cardiology, 2017, 240, 253-257.	0.8	4
25	Bioimpedance Vectorial Analyses in Cardiorenal Syndrome. , 2017, , 171-176.		0
26	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Postâ€Hoc Analysis of the GISSIâ€HF (Gruppo Italiano per lo Studio della Sopravvivenza nella) Tj ETQq0	) 01QorgBT	/Osnerlock 10
27	Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 113-122.	1.5	5
28	The future of telemedicine for the management of heart failure patients: a Consensus Document of the Italian Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.). European Heart Journal Supplements, 2017, 19, D113-D129.	0.0	30
29	ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. European Heart Journal Supplements, 2017, 19, D102-D112.	0.0	13
30	Sacubitril/Valsartan in Clinical Practice: The Italian Experience. Cardiology, 2017, 138, 1-2.	0.6	4
31	ANMCO/SIC Consensus Document: cardiology networks for outpatient heart failure care. European Heart Journal Supplements, 2017, 19, D89-D101.	0.0	12
32	Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials. Monaldi Archives for Chest Disease, 2017, 87, 805.	0.3	5
33	Prevalence of job-related distress and satisfaction in a nationwide cardiology setting. Journal of Cardiovascular Medicine, 2016, 17, 587-594.	0.6	5
34	The 30â€day metric in acute heart failure revisited: data from <scp>INâ€HF</scp> Outcome, an Italian nationwide cardiology registry. European Journal of Heart Failure, 2015, 17, 1032-1041.	2.9	32
35	Regular Wine Consumption in Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 428-437.	1.6	26
36	Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 977-993.	1.5	1

#	Article	IF	CITATIONS
37	Modulation of cardiac cytochrome P450 in patients with heart failure. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 327-339.	1.5	15
38	Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Failure Reviews, 2014, 19, 237-246.	1.7	27
39	Ultrafiltration in Refractory Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1658-1659.	1.2	2
40	Natriuretic peptides in acute chest pain and acute coronary syndrome. Coronary Artery Disease, 2013, 24, 33-39.	0.3	3
41	Emergency reversal of vitamin-K antagonists related over-anticoagulation: case report and brief overview on the role of Prothrombin Complex Concentrate. Monaldi Archives for Chest Disease, 2013, 80, 184-8.	0.3	3
42	Diagnosis and Management of Fluid Overload in Heart Failure and Cardio-Renal Syndrome: The "5B― Approach. Seminars in Nephrology, 2012, 32, 129-141.	0.6	70
43	Role of Bioimpedance Vectorial Analysis in Cardio-Renal Syndromes. Seminars in Nephrology, 2012, 32, 93-99.	0.6	16
44	Extracorporeal Ultrafiltration in Heart Failure and Cardio-Renal Syndromes. Seminars in Nephrology, 2012, 32, 100-111.	0.6	7
45	Minor Myocardial Damage is a Prevalent Condition in Patients With Acute Heart Failure Syndromes and Preserved Systolic Function With Long-Term Prognostic Implications. A Report From the CIAST-HF (Collaborative Italo-Argentinean Study on Cardiac Troponin T in Heart Failure) Study. Journal of Cardiac Failure, 2012, 18, 822-830.	0.7	26
46	Prognostic value of B-type natriuretic peptide in patients with left bundle-branch block admitted for acute heart failure. European Journal of Internal Medicine, 2011, 22, e152-e154.	1.0	3
47	Management and monitoring of haemodynamic complications in acute heart failure. Heart Failure Reviews, 2011, 16, 575-581.	1.7	8
48	Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Failure Reviews, 2011, 16, 519-529.	1.7	95
49	Biomarkers in kidney and heart disease. Nephrology Dialysis Transplantation, 2011, 26, 62-74.	0.4	46
50	Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1049-1063.	1.5	12
51	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1416-1420.	0.4	118
52	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1777-1784.	0.4	31
53	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1406-1416.	0.4	188
54	Use of Brain Natriuretic Peptide and Bioimpedance to Guide Therapy in Heart Failure Patients. Contributions To Nephrology, 2010, 164, 209-216.	1.1	19

#	Article	IF	CITATIONS
55	Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contributions To Nephrology, 2010, 165, 54-67.	1.1	106
56	How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure?. International Journal of Cardiology, 2010, 140, 88-94.	0.8	26
57	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. European Heart Journal, 2010, 31, 703-711.	1.0	797
58	ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation, 2010, 25, 2077-2089.	0.4	35
59	Myocardial Damage Is a Prevalent Condition with Long-Term Prognostic Implications in Patients with Acute Heart Failure Syndromes and Preserved Systolic Function. A Report from the CIAST-HF (Collaborative Italo-Argentinean Study on Cardiac Troponin-T in Heart Failure) Study. Journal of Cardiac Failure 2009 15, S95-S96	0.7	0
60	Additive prognostic value of cardiopulmonary exercise testing in elderly patients with heart failure. Clinical Science, 2009, 116, 415-422.	1.8	11
61	Prognostic value of brain natriuretic peptide and enhanced ventilatory response to exercise in patients with chronic heart failure. Internal and Emergency Medicine, 2008, 3, 331-337.	1.0	9
62	Inpatient Monitoring and Prognostic Importance of Bâ€Type Natriuretic Peptide. Congestive Heart Failure, 2008, 14, 30-34.	2.0	12
63	Bâ€ <b>T</b> ype Natriuretic Peptide: Application in the Community. Congestive Heart Failure, 2008, 14, 12-16.	2.0	3
64	Bâ€ <b>T</b> ype Natriuretic Peptide: Application in the Community. Congestive Heart Failure, 2008, 14, 12-16.	2.0	7
65	Inpatient Monitoring and Prognostic Importance of Bâ€Type Natriuretic Peptide. Congestive Heart Failure, 2008, 14, 30-34.	2.0	13
66	Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: A retrospective study. International Journal of Cardiology, 2008, 126, 400-406.	0.8	40
67	B-Type Natriuretic Peptide–Guided Treatment for Predicting Outcome in Patients Hospitalized in Sub–Intensive Care Unit With Acute Heart Failure. Journal of Cardiac Failure, 2008, 14, 219-224.	0.7	61
68	Plasma Brain Natriuretic Peptide Predicts Short-Term Clinical Outcome in Heart Failure Patients With Restrictive Filling Pattern. Journal of Cardiac Failure, 2008, 14, 420-425.	0.7	22
69	State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure, 2008, 10, 824-839.	2.9	691
70	Brain natriuretic peptide plasma level is a reliable indicator of advanced diastolic dysfunction in patients with chronic heart failure. European Journal of Echocardiography, 2007, 8, 30-36.	2.3	9
71	The cardiopulmonary exercise test is safe and reliable in elderly patients with chronic heart failure. Journal of Cardiovascular Medicine, 2007, 8, 608-612.	0.6	23
72	Multiparametric Risk Stratification in Patients With Mild to Moderate Chronic Heart Failure. Journal of Cardiac Failure, 2007, 13, 445-451.	0.7	11

#	Article	IF	CITATIONS
73	Prognostic role of B-type natriuretic peptide in patients with diabetes and acute decompensated heart failure. Diabetic Medicine, 2007, 24, 124-130.	1.2	15
74	Correlation between Cognitive Impairment and Prognostic Parameters in Patients with Congestive Heart Failure. Archives of Medical Research, 2007, 38, 234-239.	1.5	39
75	Bâ€Type Natriuretic Peptide Predicts Postdischarge Prognosis in Elderly Patients Admitted Due to Cardiogenic Pulmonary Edema. The American Journal of Geriatric Cardiology, 2006, 15, 202-207.	0.7	19
76	Early diagnosis of congestive heart failure: clinical utility of B-type natriuretic peptide testing associated with Doppler echocardiography. Journal of Cardiovascular Medicine, 2006, 7, 406-413.	0.6	16
77	The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. European Journal of Echocardiography, 2006, 7, 40-44.	2.3	42
78	Rapid Brain Natriuretic Peptide Test and Doppler Echocardiography for Early Diagnosis of Mild Heart Failure. Clinical Chemistry, 2006, 52, 1802-1808.	1.5	15
79	Brain natriuretic peptide is a reliable indicator of ventilatory abnormalities during cardiopulmonary exercise test in heart failure patients. Medical Science Monitor, 2006, 12, CR191-5.	0.5	4
80	Prognostic Value of Plasma Brain Natriuretic Peptide, Urea Nitrogen, and Creatinine in Outpatients >70 Years of Age With Heart Failure. American Journal of Cardiology, 2005, 96, 705-709.	0.7	40
81	The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. European Journal of Heart Failure, 2005, 7, 542-551.	2.9	25
82	B-Type Natriuretic Peptide Can Predict the Medium-Term Risk in Patients With Acute Heart Failure and Preserved Systolic Function. Journal of Cardiac Failure, 2005, 11, 498-503.	0.7	46
83	Recommendations for the clinical use of cardiac natriuretic peptides. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 430-46.	0.1	5
84	Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: A report from the Italian network on congestive heart failure. American Heart Journal, 2002, 143, 398-405.	1.2	681
85	Coronary Flow Reserve of Normal Left Anterior Descending Artery in Patients with Ischemic Heart Disease: A Transesophageal Doppler Study. Journal of the American Society of Echocardiography, 1999, 12, 720-728.	1.2	12
86	Multicenter trial on prognostic value of inducible ischemia, assessed by dobutamine stress echocardiography and exercise electrocardiography test, in patients with uncomplicated myocardial infarction, treated with thrombolytic therapy. International Journal of Cardiovascular Imaging, 1998, 14, 155-162	0.2	1
87	A 3-Year Single Center Experience With Left Atrial Pressure Remote Monitoring: The Long and Winding Road. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6